Lowe Brockenbrough & Co’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.5M Sell
27,005
-256
-0.9% -$91.3K 0.47% 55
2025
Q4
$8.92M Buy
27,261
+116
+0.4% +$36.8K 0.44% 62
2025
Q3
$7.66M Buy
27,145
+750
+3% +$218K 0.39% 63
2025
Q2
$7.37M Buy
26,395
+1,991
+8% +$564K 0.41% 63
2025
Q1
$7.6M Buy
24,404
+80
+0.3% +$23.6K 0.5% 60
2024
Q4
$6.34M Sell
24,324
-312
-1% -$92.6K 0.41% 66
2024
Q3
$7.94M Sell
24,636
-9,395
-28% -$3.07M 0.51% 58
2024
Q2
$10.6M Sell
34,031
-47
-0.1% -$13.8K 0.71% 42
2024
Q1
$9.69M Buy
34,078
+9,033
+36% +$2.64M 0.65% 49
2023
Q4
$7.21M Sell
25,045
-11,205
-31% -$3.05M 0.56% 55
2023
Q3
$9.74M Sell
36,250
-137
-0.4% -$34.2K 0.76% 40
2023
Q2
$8.08M Buy
36,387
+3,261
+10% +$757K 0.61% 54
2023
Q1
$8.01M Buy
33,126
+1,956
+6% +$480K 0.65% 53
2022
Q4
$8.19M Sell
31,170
-1,624
-5% -$435K 0.71% 49
2022
Q3
$7.39M Sell
32,794
-1,419
-4% -$344K 0.71% 48
2022
Q2
$8.32M Sell
34,213
-381
-1% -$93.4K 0.73% 42
2022
Q1
$8.37M Sell
34,594
-765
-2% -$176K 0.62% 55
2021
Q4
$7.96M Buy
35,359
+580
+2% +$122K 0.58% 57
2021
Q3
$7.4M Buy
34,779
+3,090
+10% +$711K 0.58% 54
2021
Q2
$7.72M Buy
31,689
+517
+2% +$127K 0.7% 46
2021
Q1
$7.76M Buy
31,172
+425
+1% +$101K 0.75% 48
2020
Q4
$7.07M Buy
30,747
+204
+0.7% +$47K 0.77% 46
2020
Q3
$7.76M Sell
30,543
-337
-1% -$83.5K 0.97% 33
2020
Q2
$7.28M Sell
30,880
-421
-1% -$96.1K 0.98% 33
2020
Q1
$6.35M Sell
31,301
-369
-1% -$80.6K 1.05% 29
2019
Q4
$7.63M Buy
31,670
+1,290
+4% +$284K 0.95% 37
2019
Q3
$5.88M Buy
30,380
+155
+0.5% +$29.8K 0.79% 42
2019
Q2
$5.57M Buy
30,225
+153
+0.5% +$27.4K 0.76% 47
2019
Q1
$5.71M Buy
30,072
+69
+0.2% +$13.2K 0.8% 40
2018
Q4
$5.84M Sell
30,003
-330
-1% -$64.4K 0.95% 36
2018
Q3
$6.29M Sell
30,333
-150
-0.5% -$29.6K 0.88% 38
2018
Q2
$5.63M Buy
30,483
+1,417
+5% +$251K 0.83% 41
2018
Q1
$4.96M Sell
29,066
-305
-1% -$56K 0.73% 47
2017
Q4
$5.11M Sell
29,371
-95
-0.3% -$16.8K 0.73% 45
2017
Q3
$5.49M Sell
29,466
-50
-0.2% -$8.86K 0.84% 42
2017
Q2
$5.08M Buy
29,516
+346
+1% +$56.3K 0.8% 46
2017
Q1
$4.79M Buy
29,170
+127
+0.4% +$21.1K 0.76% 48
2016
Q4
$4.25M Sell
29,043
-13,655
-32% -$2.06M 0.71% 52
2016
Q3
$7.12M Buy
42,698
+181
+0.4% +$30.6K 1.23% 24
2016
Q2
$6.47M Buy
42,517
+873
+2% +$136K 1.13% 29
2016
Q1
$6.24M Buy
41,644
+770
+2% +$114K 1.07% 30
2015
Q4
$6.63M Sell
40,874
-657
-2% -$103K 1.13% 27
2015
Q3
$5.75M Sell
41,531
-220
-0.5% -$34.7K 1% 35
2015
Q2
$6.41M Sell
41,751
-1,535
-4% -$246K 1.03% 33
2015
Q1
$6.92M Buy
43,286
+2,655
+7% +$418K 1.09% 29
2014
Q4
$6.47M Sell
40,631
-7,980
-16% -$1.24M 1.03% 36
2014
Q3
$6.83M Sell
48,611
-178
-0.4% -$23.2K 1.09% 30
2014
Q2
$5.78M Buy
48,789
+2,422
+5% +$280K 0.92% 43
2014
Q1
$5.72M Sell
46,367
-1,045
-2% -$127K 0.95% 41
2013
Q4
$5.41M Sell
47,412
-2,061
-4% -$234K 0.89% 47
2013
Q3
$5.54M Sell
49,473
-115
-0.2% -$12.5K 1.01% 40
2013
Q2
$4.89M Buy
+49,588
New +$5.15M 0.91% 46

Other funds holding AMGN

Lowe Brockenbrough & Co's AMGN Position: Q1 2026 in Review

Lowe Brockenbrough & Co reduced its Amgen (AMGN) stake by 0.94% in Q1 2026, selling an estimated $91.3K and leaving 27,005 shares worth $9.5M. The position accounts for 0.47% of the portfolio, ranked #55.

Lowe Brockenbrough & Co first reported a position in AMGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.6M in Q2 2024. 3,126 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Lowe Brockenbrough & Co held 27,005 shares of Amgen worth $9.5M as of Q1 2026.
  • Lowe Brockenbrough & Co sold 256 Amgen shares in Q1 2026, an estimated $91.3K.
  • Amgen made up 0.47% of Lowe Brockenbrough & Co's portfolio in Q1 2026, its #55 holding.
  • Lowe Brockenbrough & Co first reported a position in Amgen in Q2 2013 and has held it in 52 quarters since.
  • Lowe Brockenbrough & Co's Amgen position peaked at $10.6M in Q2 2024.
  • 3,126 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Lowe Brockenbrough & Co's 13F filing for Q1 2026, filed 7 May 2026.